|
Amnesia
|
0.510 |
Biomarker
|
disease |
CTD_human |
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
|
11125734 |
1999 |
|
Amnesia
|
0.510 |
Biomarker
|
disease |
BEFREE |
Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats.
|
30863075 |
2019 |
|
Amnesia
|
0.510 |
Biomarker
|
disease |
RGD |
Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
|
17276409 |
2007 |
|
Memory Disorders
|
0.300 |
Biomarker
|
disease |
CTD_human |
Effect of endogenous histamine in the ventral hippocampus on fear memory deficits induced by scopolamine as evaluated by step-through avoidance response in rats.
|
16488453 |
2006 |
|
Obesity
|
0.230 |
Biomarker
|
disease |
RGD |
The present study suggests that antagonistic targeting of the histamine H(3) receptor decreases food intake, body weight, and plasma TG levels and, thus, represents an interesting approach to treatment of obesity and associated hyperlipidemia.
|
17189541 |
2006 |
|
Obesity
|
0.230 |
Biomarker
|
disease |
BEFREE |
Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
|
23591112 |
2013 |
|
Obesity
|
0.230 |
Biomarker
|
disease |
BEFREE |
Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).
|
23591110 |
2013 |
|
Obesity
|
0.230 |
Biomarker
|
disease |
BEFREE |
Histamine H(3) receptor antagonists are potential therapeutic agents for cognitive dysfunction, epilepsy, hypersomnia and obesity.
|
16316645 |
2006 |
|
Status Epilepticus
|
0.210 |
Biomarker
|
disease |
RGD |
Transient changes in the limbic histaminergic system after systemic kainic acid-induced seizures.
|
16137576 |
2005 |
|
Status Epilepticus
|
0.210 |
Biomarker
|
disease |
BEFREE |
The Neuroprotective Effects of Histamine H3 Receptor Antagonist E177 on Pilocarpine-Induced Status Epilepticus in Rats.
|
31739417 |
2019 |
|
Amnestic Disorder
|
0.200 |
Biomarker
|
disease |
RGD |
Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
|
17276409 |
2007 |
|
Hyperemia
|
0.200 |
Biomarker
|
disease |
RGD |
The increase in the volume of blood accumulating during RH (RH-volume), the peak increase of arterial blood flow (RH-peak response) and the duration of the hyperemia (RH-duration) were used to quantify RH after occluding the anterior mesenteric artery for 30, 60 and 120 s. Hyperemia parameters were determined before and after administration of the selective histamine H3 receptor antagonist clobenpropit.
|
15381834 |
2004 |
|
Hyperglycemia
|
0.200 |
Biomarker
|
disease |
RGD |
Effect of L-carnosine on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats.
|
11684344 |
2001 |
|
Reperfusion Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Since facilitation of central histaminergic activity ameliorates reperfusion injury, effects of postischemic administration of L-histidine, a precursor of histamine, and thioperamide, a histamine H3 receptor antagonist, on inflammatory cell infiltration were evaluated in a rat model of transient occlusion of the middle cerebral artery.
|
17169356 |
2007 |
|
Gastric ulcer
|
0.200 |
Biomarker
|
disease |
RGD |
Role of capsaicin-sensitive nerves and histamine H1, H2, and H3 receptors in the gastroprotective effect of histamine against stress ulcers in rats.
|
15680274 |
2005 |
|
Sciatic Neuropathy
|
0.200 |
Biomarker
|
disease |
RGD |
Histaminergic involvement in neuropathic pain produced by partial ligation of the sciatic nerve in rats.
|
17350523 |
2007 |
|
Visual seizure
|
0.200 |
Biomarker
|
disease |
RGD |
Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia.
|
15319804 |
2004 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
We assessed the safety and efficacy of pitolisant, a histamine H3 receptor inverse agonist, for treatment of cataplexy in patients with narcolepsy.
|
28129985 |
2017 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy.
|
31838740 |
2020 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
Pitolisant, a selective inverse agonist for the histamine H3 receptor, is a new treatment for adults suffering from narcolepsy.
|
30771351 |
2019 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
|
18295497 |
2008 |
|
Impaired cognition
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
A partial agonist and a full antagonist of the histamine H3 receptor have been suggested to have therapeutic effects on cognitive deficits in psychiatric disorders.
|
28863002 |
2018 |
|
Impaired cognition
|
0.030 |
Biomarker
|
disease |
BEFREE |
Compound <b>3p</b> has been identified as a very promising lead, showing good Ca<sup>2+</sup> channels blockade activity (IC<sub>50</sub> = 21 ± 1 μM), potent affinity against hH3R (<i>K</i><sub>i</sub> = 565 ± 62 nM), a moderate but selective hBuChE inhibition (IC<sub>50</sub> = 7.83 ± 0.10 μM), strong antioxidant power (3.6 TE), and ability to restore cognitive impairment induced by lipopolysaccharide.
|
31724859 |
2019 |
|
Impaired cognition
|
0.030 |
Biomarker
|
disease |
BEFREE |
Histamine H(3) receptor antagonists are potential therapeutic agents for cognitive dysfunction, epilepsy, hypersomnia and obesity.
|
16316645 |
2006 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Histamine H3 receptor antagonists are currently being evaluated for their potential use in a number of central nervous system disorders including Alzheimer's Disease (AD).
|
19222483 |
2009 |